| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The rattlesnake-derived metalloprotease-fragment which is referred to as the alfimeprase has strong fibrinolysis activity without hemorrhagic activity and does not show any adverse effect like the rtPA. The alfimeprase went in clinical development, but it was rapidly degraded by the alfa-2 macroglobulin in the blood vein, that resulted in no good efficacy. We have focused on the Taiwan habu-derived toxin TM3(fibrinlysin) and developed the research on the clot-dissolving agent.
|
